Melflufen, a peptide‐conjugated alkylator, is an efficient anti‐neo‐plastic drug in breast cancer cell lines

Melphalan flufenamide (hereinafter referred to as “melflufen”) is a peptide‐conjugated drug currently in phase 3 trials for the treatment of relapsed or refractory multiple myeloma. Due to its lipophilic nature, it readily enters cells, where it is converted to the known alkylator melphalan leading...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancer Med
Hlavní autoři: Schepsky, Alexander, Traustadottir, Gunnhildur Asta, Joelsson, Jon Petur, Ingthorsson, Sævar, Kricker, Jennifer, Bergthorsson, Jon Thor, Asbjarnarson, Arni, Gudjonsson, Thorkell, Nupponen, Nina, Slipicevic, Ana, Lehmann, Fredrik, Gudjonsson, Thorarinn
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2020
Témata:
Cancer Biology
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7520280/
https://ncbi.nlm.nih.gov/pubmed/32717133
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.3300
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky